ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BASF has invested an undisclosed sum in the molecular biology start-up 3Helix. The firm makes specialized peptides that bind to damaged collagen molecules. 3Helix has so far commercialized its technology for medical imaging and diagnostic applications. BASF will gain exclusive rights to commercialize 3Helix’s platform for personal care applications, where a wide range of firms are building antiaging products around supporting or supplementing collagen in skin.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X